Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist

In this study, we present the translational modeling used in the discovery of AZD1979, a melanin‐concentrating hormone receptor 1 (MCHr1) antagonist aimed for treatment of obesity. The model quantitatively connects the relevant biomarkers and thereby closes the scaling path from rodent to man, as well as from dose to effect level. The complexity of individual modeling steps depends on the quality and quantity of data as well as the prior information; from semimechanistic body‐composition models to standard linear regression. Key predictions are obtained by standard forward simulation (e.g., predicting effect from exposure), as well as non‐parametric input estimation (e.g., predicting energy intake from longitudinal body‐weight data), across species. The work illustrates how modeling integrates data from several species, fills critical gaps between biomarkers, and supports experimental design and human dose‐prediction. We believe this approach can be of general interest for translation in the obesity field, and might inspire translational reasoning more broadly.

[1]  J. Speakman,et al.  Effects of a specific MCHR1 antagonist (GW803430) on energy budget and glucose metabolism in diet‐induced obese mice , 2014, Obesity.

[2]  Jeremiah Stamler,et al.  The impact of eating frequency and time of intake on nutrient quality and Body Mass Index: the INTERMAP Study, a Population-Based Study. , 2015, Journal of the Academy of Nutrition and Dietetics.

[3]  J. Perrard,et al.  Effect of the Cannabinoid Receptor‐1 Antagonist Rimonabant on Inflammation in Mice With Diet‐Induced Obesity , 2011, Obesity.

[4]  Tove Tuntland,et al.  Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research , 2014, Front. Pharmacol..

[5]  A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects , 2004 .

[6]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[7]  Joel Andersson,et al.  A General-Purpose Software Framework for Dynamic Optimization (Een algemene softwareomgeving voor dynamische optimalisatie) , 2013 .

[8]  N. Weissman,et al.  Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.

[9]  Magnus Trägårdh,et al.  Input estimation for drug discovery using optimal control and Markov chain Monte Carlo approaches , 2016, Journal of Pharmacokinetics and Pharmacodynamics.

[10]  A. Rissanen,et al.  Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. , 2008, European heart journal.

[11]  T. R. Johnson,et al.  Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin , 2016, The AAPS Journal.

[12]  M. Danhof,et al.  Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.

[13]  Smith Ig,et al.  Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. , 2001, The Journal of family practice.

[14]  S. Hjorth,et al.  Modeling energy intake by adding homeostatic feedback and drug intervention , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[15]  Hazhir Rahmandad,et al.  Human Growth and Body Weight Dynamics: An Integrative Systems Model , 2014, PloS one.

[16]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[17]  M. Gold,et al.  The next generation of obesity treatments: beyond suppressing appetite , 2013, Front. Psychol..

[18]  S. Woods,et al.  Assessment of feeding behavior in laboratory mice. , 2010, Cell metabolism.

[19]  D. Macneil,et al.  Effects of a Novel Y5 Antagonist in Obese Mice: Combination With Food Restriction or Sibutramine , 2008, Obesity.

[20]  E. Maratos-Flier,et al.  Expression of melanin-concentrating hormone receptor 2 protects against diet-induced obesity in male mice. , 2014, Endocrinology.

[21]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[22]  M. Pfister,et al.  Exploratory Literature Meta‐Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds , 2017, Journal of clinical pharmacology.

[23]  Mingzhu Zhang,et al.  1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[24]  M. Goulder,et al.  Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. , 2001, The Journal of family practice.

[25]  J. Le Magnen,et al.  [The spontaneous periodicity of ad libitum food intake in white rats]. , 1966, Journal de physiologie.

[26]  Corby K. Martin,et al.  Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. , 2011, Journal of Clinical Endocrinology and Metabolism.

[27]  K Gadkar,et al.  A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.

[28]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[29]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[30]  P. Gennemark,et al.  Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties. , 2016, Journal of medicinal chemistry.

[31]  L. Aronne,et al.  A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study , 2010, International Journal of Obesity.

[32]  R. Maldonado,et al.  Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant , 2010, Journal of neurochemistry.

[33]  Andrew Hughes,et al.  Model-based drug discovery: implementation and impact. , 2013, Drug discovery today.

[34]  Dhaval K. Shah,et al.  Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[35]  CM Friedrich,et al.  A model qualification method for mechanistic physiological QSP models to support model‐informed drug development , 2016, CPT: pharmacometrics & systems pharmacology.

[36]  D. Macneil,et al.  Mechanism of the anti‐obesity effects induced by a novel Melanin‐concentrating hormone 1‐receptor antagonist in mice , 2010, British journal of pharmacology.

[37]  Carson C. Chow,et al.  Quantification of the effect of energy imbalance on bodyweight , 2011, The Lancet.

[38]  S. Majumdar,et al.  Drug treatments for obesity: orlistat, sibutramine, and rimonabant , 2007, The Lancet.

[39]  Juen Guo,et al.  Predicting Changes of Body Weight, Body Fat, Energy Expenditure and Metabolic Fuel Selection in C57BL/6 Mice , 2011, PloS one.

[40]  H. Hauner,et al.  Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[41]  P. Gennemark,et al.  Effects of a novel potent melanin‐concentrating hormone receptor 1 antagonist, AZD1979, on body weight homeostasis in mice and dogs , 2016, British journal of pharmacology.

[42]  Kevin D. Hall,et al.  Quantifying Energy Intake Changes during Obesity Pharmacotherapy , 2014, Obesity.

[43]  A. Rissanen,et al.  A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects , 2004, International Journal of Obesity.

[44]  H. Jackson,et al.  The utility of animal models to evaluate novel anti‐obesity agents , 2011, British journal of pharmacology.

[45]  P. Fletcher,et al.  Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity , 2014, Pharmacology research & perspectives.

[46]  Douglas Ferguson,et al.  Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[47]  P. Vicini,et al.  Translation of Anticancer Efficacy From Nonclinical Models to the Clinic , 2014, CPT: pharmacometrics & systems pharmacology.

[48]  E. Scharrer,et al.  Influence of age and hepatic branch vagotomy on the night/day distribution of food intake in rats , 1993, Zeitschrift fur Ernahrungswissenschaft.

[49]  J. Holenz,et al.  Chronic 5‐HT6 receptor modulation by E‐6837 induces hypophagia and sustained weight loss in diet‐induced obese rats , 2006, British journal of pharmacology.

[50]  K. Gadde,et al.  Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) , 2011, Obesity.

[51]  C. Musante,et al.  PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates , 2016, Journal of Pharmacokinetics and Pharmacodynamics.

[52]  Hui C. Ko,et al.  Convergence of direct and indirect pharmacodynamic response models , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[53]  Keith W Ward,et al.  A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[54]  Jangir Selimkhanov,et al.  Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies , 2016, PloS one.

[55]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[57]  N. Moore,et al.  From preclinical to clinical development: The example of a novel treatment for obesity , 2014, Neurobiology of Disease.

[58]  Yifeng Lu,et al.  Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans , 2011, The AAPS Journal.

[59]  Johan Gabrielsson,et al.  A modeling approach for compounds affecting body composition , 2013, Journal of Pharmacokinetics and Pharmacodynamics.